All articles tagged with #drug failure
Originally Published 13 days ago — by Reuters
Ultragenyx Pharmaceutical's experimental drug setrusumab for osteogenesis imperfecta failed to reduce fracture rates in late-stage studies, leading to a 43.5% drop in its stock price and potential discontinuation of the program, despite improvements in bone mineral density.
Originally Published 13 days ago — by Endpoints News
Ultragenyx and Mereo's late-stage clinical trial for a rare bone disease drug has failed, marking a significant setback for the development program.
Originally Published 4 months ago — by Investor's Business Daily
Summit Therapeutics' stock plummeted nearly 17% after its experimental drug, ivonescimab, failed to improve overall survival in a lung cancer trial, casting doubt on its prospects for FDA approval and future partnerships.
Originally Published 7 months ago — by Investor's Business Daily
Regeneron Pharmaceuticals' stock dropped 12% after its COPD drug, developed with Sanofi, failed in a Phase 3 trial, with mixed results across two studies, potentially hindering approval efforts.
Originally Published 1 year ago — by STAT
Amylyx Pharmaceuticals' drug Relyvrio, approved for ALS treatment in 2022, has failed to outperform a placebo in a pivotal study, prompting discussions about its removal from the market and raising questions about the FDA's decision to authorize it. The disappointing results have left ALS patients, advocates, and researchers grappling with the next steps in light of the drug's lack of efficacy, highlighting the challenges of regulatory leniency for treatments of devastating, incurable diseases.
Originally Published 2 years ago — by Fortune
Bayer AG experienced its largest drop in market value ever, losing about €7.6 billion ($8.3 billion), as its shares fell by as much as 19% in Frankfurt trading to the lowest level in over a decade. The German company faced major setbacks, including the discontinuation of a key drug study due to lack of efficacy and a significant trial loss against its weed killer Roundup, resulting in a $1.5 billion verdict. These challenges increase pressure on the new CEO, Bill Anderson, to outline a turnaround plan, potentially including a breakup of the conglomerate.
Originally Published 2 years ago — by Investor's Business Daily
Biotech company Ventyx Biosciences saw its stock plummet by over 80% after its psoriasis drug, VTX958, failed to meet efficacy expectations in Phase 2 testing. Only two out of four doses showed statistically significant improvements in symptoms, leading the company to abandon further development in the highly competitive psoriasis market. Ventyx is terminating the psoriasis study and an ongoing test in psoriatic arthritis but will continue studying VTX958 in patients with Crohn's disease.
Originally Published 2 years ago — by Investor's Business Daily
Biotech company FibroGen's stock crashed to a record low after its lead asset, pamrevlumab, failed to meet the preset bar for treating idiopathic pulmonary fibrosis. This is the second failure for the drug, which also failed to make a difference in Duchenne muscular dystrophy earlier this month. FibroGen will scrap two final-phase studies of pamrevlumab in idiopathic pulmonary fibrosis and work to extend its cash runway in 2026 through a cost-cutting plan. The fall of FibroGen stock marked a record low in massive volume.